diabetes
Eli Lilly drops development of diabetes drug in Phase III
April 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
Novo Nordisk breaks ground on new $2 billion production facility in North Carolina
March 29, 2016Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility
Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
Sun Pharma agree deal to distribute AstraZeneca type-2 diabetes drug in India
March 24, 2016Sales and Marketing AstraZeneca, India, Sun Pharma, diabetes, oxra, type 2, type-2
Sun Pharma has agreed a deal with AstraZeneca to promote and distribute their type-2 diabetes drug, dapagliflozin, in India. Marketed …
Cellnovo, Roche sign deal to integrate diabetes platforms
March 15, 2016Manufacturing and Production, Sales and Marketing Cellnovo, Roche, diabetes
Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug major Roche (Euronext: ROG) to …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Bayer and Baxalta in separate €1 billion-plus deals
January 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Novo Nordisk files for new insulin approval
December 10, 2015Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application
Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
Lilly pulls plug on basal insulin Peglispro
December 8, 2015Manufacturing and Production R&D, basal insulin peglispro, diabetes, lilly, peglispro, phase III failure
Lilly has decided to pull out of filing its diabetes drug basal insulin peglispro, after failing to convince regulators and …
Novo Nordisk buys Xoma diabetes program and scores trial successes
December 2, 2015Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes
Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …
Personalised care key to diabetes management, says NICE
December 2, 2015Research and Development NICE, NICE guidelines, diabetes, type 2 diabetes
UK drugs regulator NICE has published updated guidelines on type 2 diabetes, saying that taking an individualised approach to care …
Featured Market Report: Type 2 Diabetes – Epidemiology Forecast to 2024
November 16, 2015Manufacturing and Production, Research and Development diabetes, market reports
Diabetes is one of the most common non-communicable diseases worldwide and is an escalating public health problem globally, with an …
Janssen buys licence to diabetes and obesity drugs from Hanmi
November 10, 2015Manufacturing and Production, Research and Development Janssen, diabetes, hanmi
Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity. …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Sanofi and Hanmi partner to create long-acting diabetes treatments
November 5, 2015Manufacturing and Production, Research and Development Korea, Sanofi, diabetes, hanmi
Sanofi and Hanmi Pharmaceutical have announced a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments. Korea’s …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
